Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

303
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
303
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

600
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
600

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Choosing Covariate Balancing Methods for Causal Inference: Practical Insights From a Simulation Study.

Statistics in medicine·2026
Same author

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same author

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.

EBioMedicine·2026
Same author

Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.

medRxiv : the preprint server for health sciences·2026
Same author

Gene set analysis for time-to-event outcome: comparison of a new approach based on the generalized Berk-Jones statistic with existing methods in presence of intra gene-set correlation.

Briefings in bioinformatics·2026

Related Experiment Video

Updated: May 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K

Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast-Track Regulatory

Moreno Ursino1, Sandrine Boulet1, Corinne Collignon2

  • 1Inserm, Inria, Université Paris Cité, UMRS 1346, HeKA, Paris, France.

Statistics in Medicine
|May 5, 2026
PubMed
Summary
This summary is machine-generated.

A new statistical framework aids health technology assessment for digital medical devices (DMDs) by integrating clinical trial data and real-world data (RWD). This approach supports provisional access and informed final decisions for innovative medical technologies.

Keywords:
Bayesianinterim analysismeta‐analysisrandomized clinical trialreal‐world data

More Related Videos

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

3.1K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

14.2K

Related Experiment Videos

Last Updated: May 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K
Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
10:42

Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics

Published on: June 17, 2022

3.1K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

14.2K

Area of Science:

  • Health Technology Assessment
  • Biostatistics
  • Medical Device Regulation

Background:

  • European health technology assessment (HTA) authorities offer provisional access pathways for digital medical devices (DMDs) due to patient demand for innovation.
  • These pathways are utilized when clinical trial data is incomplete, and clinical benefits remain uncertain even post-CE marking.

Purpose of the Study:

  • To propose a statistically principled framework for evaluating DMDs under European HTA fast-track requirements.
  • To integrate both clinical trial data and real-world data (RWD) for a comprehensive DMD evaluation.

Main Methods:

  • A three-step framework: interim analysis of clinical trial data, final analysis of clinical trial data, and meta-analysis combining clinical trial data with RWD.
  • Introduction of metrics to optimize the timing of interim analysis and temporary authorization applications.
  • Assessment of the framework through an extensive simulation study.

Main Results:

  • The proposed framework facilitates the integration of incomplete clinical trial data with subsequent RWD.
  • It supports temporary regulatory authorization, enabling RWD collection for DMDs.
  • The framework provides a statistically sound method for final decision-making.

Conclusions:

  • The framework is suitable for DMD evaluation under European HTA fast-track requirements.
  • It enhances decision-making by leveraging both clinical trial data and RWD.
  • A complementary post-market evaluation, akin to phase IV studies, is recommended after widespread adoption.